HOME >> BIOLOGY >> NEWS
Early dexamethasone exposure has long-term neurodevelopment, neuroendocrine effects

(June 28, 2004) -- Bethesda, MD -- Any parent of a newborn with extremely low birth weight (ELBW) faces the possibility that their child will be diagnosed with severe respiratory distress syndrome, which results in ventilator and/or oxygen dependency, and subsequent onset of chronic lung disease. Until recently, early administration of a prolonged course of postnatal dexamethasone was recommended to decrease the pulmonary inflammatory process during the early neonatal period. This approach changed, however, following a Taiwanese study that demonstrated a significant increase in neurodevelopmental dysfunction in neonates treated with dexamethasone.

Background

The Taiwanese conclusions were reached within the context that the window of exposure to dexamethasone in critically ill ELBW infants spans an extensive period of perinatal viability, ranging from 24 to 40 weeks post-conception. It is during this time that the human brain undergoes significant structural and functional transformations, thereby making it particularly vulnerable to external influences.

Clinical studies examining acute dexamethasone effects on physiology and central nervous system function in premature infants have been limited.

Past research into premature infants who received prolonged dexamethasone therapy experience reduced linear growth, decreased weight gain, and smaller head circumferences. During the acute phase of dexamethasone exposure, changes in gross neuromotor function have also been noted. As a result, use of dexamethasone to improve pulmonary function in ventilator-dependent ELBW infants is undergoing significant modification towards more judicious treatment dexamethasone therapy is given less often and shorter courses are now used.

The concern remains that little is known about dexamethasone effects on long-term neurodevelopment. For obvious reasons, human testing is not desired. Researchers have previously developed a rat mo
'"/>

Contact: Mayer Resnick
mresnick@the-aps.org
301-634-7209
American Physiological Society
29-Jun-2004


Page: 1 2 3 4

Related biology news :

1. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
2. Early detection hope for eye disease
3. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
4. Early predictor of breast cancer aggressiveness
5. Early treatment confirmed as key to stroke recovery
6. Early identification of kidney disease cost-effective only when directed at high-risk patients
7. Early promise for treatment of Ebola
8. Early treatment can prevent severe vision loss in premature infants
9. Early hominids may have behaved more human than we had thought
10. Early infection and rejection detection
11. Early-life environments shape development of stress behaviors and learning abilities in mice

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/25/2016)... Unisys Corporation (NYSE: UIS ) today announced the implementation ... New York City , to help U.S. ... the United States using passports that are ... of the system at Dulles last year. The system will ... 2016. --> pilot testing of the system at ...
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... Amarantus BioScience Holdings, Inc. ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, ... (RPDD) from the US Food and Drug Administration (FDA) ... previously granted orphan drug designation (ODD) by the US ... Holdings, Inc. (OTCQB: AMBS), a biotechnology ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)... Md. , Feb. 4, 2016  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... and Uniden in the Northern District of ... moving forward.  Inter Partes Re-examination ... U.S. Patent Office.  The IPR was initiated on only ...
Breaking Biology Technology:
Cached News: